Lixisenatide
Exendin-4-derived GLP-1 receptor agonist
44 Amino Acids · MW: 4858 Da
Amino Acids
44
Molecular Weight
4858 Da
Half-life
2-4 hours
Research Score
4.3
Studies
400
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Lixisenatide?
Lixisenatide is a short-acting GLP-1 receptor agonist derived from exendin-4. It is best known for postprandial glucose control, with modest secondary weight loss in clinical use.
Key Benefits & Mechanisms
postprandial glucose control
modest weight loss
appetite reduction
short-acting option
Research Summary
Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.
Related Peptides
Oxyntomodulin
Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide
Oxyntomodulin is a naturally occurring proglucagon-derived peptide that activates GLP-1 and glucagon pathways. It is a key research tool for appetite suppression and energy balance studies in obesity.
Weight ManagementCotadutide
MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist
Cotadutide is a synthetic oxyntomodulin analogue designed to engage both GLP-1 and glucagon receptors. It was developed to improve weight loss and metabolic markers in obesity and type 2 diabetes research.
Weight ManagementMazdutide
IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist
Mazdutide is a long-acting oxyntomodulin-inspired dual agonist being developed for obesity and metabolic disease. It is designed to drive clinically meaningful weight loss while improving glucose and lipid parameters.
Weight ManagementDulaglutide
Recombinant GLP-1 receptor agonist Fc fusion protein
Dulaglutide is a long-acting GLP-1 receptor agonist used primarily in type 2 diabetes. It consistently produces modest weight loss and is widely studied as a benchmark incretin mimetic.
Weight Management